Advocate

Country: European Union

Language: German

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

imidacloprid, moxidectin

Available from:

Bayer Animal Health GmbH

ATC code:

QP54AB52

INN (International Name):

imidacloprid, moxidectin

Therapeutic group:

Dogs; Cats; Ferrets

Therapeutic area:

Antiparasitäre Produkte, Insektizide und Repellentien

Therapeutic indications:

DogsFor Hunde leiden, oder ein Risiko, gemischter parasitäre Infektionen:die Behandlung und Vorbeugung von Flohbefall (Ctenocephalides felis),die Behandlung von beißenden Läusen (Trichodectes canis),die Behandlung von Ohr-Milben-Befall (Otodectes cynotis), sarcoptic Räude (verursacht durch sarkoptes scabiei var. canis), Demodikose (verursacht durch Demodex canis),die Vorbeugung von Herzwurm-Erkrankung (L3-und L4-Larven von Dirofilaria immitis),die Behandlung von zirkulierenden mikrofilarien (Dirofilaria immitis),die Behandlung der kutanen dirofilariose (adulten Stadien von Dirofilaria repens), die Vorbeugung der kutanen dirofilariose (L3 Larven von Dirofilaria repens),die Reduktion der zirkulierenden mikrofilarien (Dirofilaria repens),die Verhinderung von angiostrongylosis (L4-Larven und unreife Erwachsene von Angiostrongylus vasorum),die Behandlung von Angiostrongylus vasorum und Crenosoma vulpis,die Prävention von spirocercosis (Spirocerca lupi),die Behandlung von Eucoleus (syn. Capillaria) boehmi (Erwachsene),die Behandlung der augenwurm Thelazia callipaeda (Erwachsene),die Behandlung von Infektionen mit gastrointestinalen Nematoden (L4-Larven, unreife Erwachsene und Erwachsene von Toxocara canis, Ancylostoma caninum und Uncinaria stenocephala, Erwachsene von Toxascaris leonina und Trichuris vulpis). Das Produkt kann als Teil einer Behandlungsstrategie für Flohallergiedermatitis (FAD) verwendet werden. CatsFor Katzen leiden, oder ein Risiko, gemischter parasitäre Infektionen:die Behandlung und Vorbeugung von Flohbefall (Ctenocephalides felis),der Behandlung von Ohr-Milben-Befall (Otodectes cynotis),der Behandlung von notoedric Räude (Notoedres cati),die Behandlung der lungworm Eucoleus aerophilus (syn. Capillaria aerophila) (Erwachsene),die Prävention von lungworm Krankheit (L3/L4-Larven von Aelurostrongylus abstrusus),die Behandlung der lungworm Aelurostrongylus abstrusus (Erwachsene),die Behandlung der augenwurm Thelazia callipaeda (Erwachsene),die Vorbeugung von Herzwurm-Erkrankung (L3-und L4-Larven von Dirofilaria immitis),die Behandlung von Infektionen mit gastrointestinalen Nematoden (L4-Larven, unreife Erwachsene und Erwachsene von Toxocara cati, und Ancylostoma tubaeforme). Das Produkt kann als Teil einer Behandlungsstrategie für Flohallergiedermatitis (FAD) verwendet werden. FerretsFor Frettchen leiden, oder ein Risiko, gemischter parasitäre Infektionen:die Behandlung und Vorbeugung von Flohbefall (Ctenocephalides felis),die Vorbeugung von Herzwurm-Erkrankung (L3-und L4-Larven von Dirofilaria immitis).

Product summary:

Revision: 23

Authorization status:

Autorisiert

Authorization date:

2003-04-02

Patient Information leaflet

                                OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
Aktuelle Informationen zu diesem Tierarzneimittel finden Sie auf der
Website mit Informationen über
Tierarzneimittel.
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
Aktuelle Informationen zu diesem Tierarzneimittel finden Sie auf der
Website mit Informationen über
Tierarzneimittel.
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 31-01-2024
Public Assessment Report Public Assessment Report Bulgarian 29-01-2024
Patient Information leaflet Patient Information leaflet Spanish 31-01-2024
Public Assessment Report Public Assessment Report Spanish 29-01-2024
Patient Information leaflet Patient Information leaflet Czech 31-01-2024
Public Assessment Report Public Assessment Report Czech 29-01-2024
Patient Information leaflet Patient Information leaflet Danish 31-01-2024
Public Assessment Report Public Assessment Report Danish 29-01-2024
Patient Information leaflet Patient Information leaflet Estonian 31-01-2024
Public Assessment Report Public Assessment Report Estonian 29-01-2024
Patient Information leaflet Patient Information leaflet Greek 31-01-2024
Public Assessment Report Public Assessment Report Greek 29-01-2024
Patient Information leaflet Patient Information leaflet English 31-01-2024
Public Assessment Report Public Assessment Report English 29-01-2024
Patient Information leaflet Patient Information leaflet French 31-01-2024
Public Assessment Report Public Assessment Report French 29-01-2024
Patient Information leaflet Patient Information leaflet Italian 31-01-2024
Public Assessment Report Public Assessment Report Italian 29-01-2024
Patient Information leaflet Patient Information leaflet Latvian 31-01-2024
Public Assessment Report Public Assessment Report Latvian 29-01-2024
Patient Information leaflet Patient Information leaflet Lithuanian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 31-01-2024
Public Assessment Report Public Assessment Report Lithuanian 29-01-2024
Patient Information leaflet Patient Information leaflet Hungarian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 31-01-2024
Public Assessment Report Public Assessment Report Hungarian 29-01-2024
Patient Information leaflet Patient Information leaflet Maltese 31-01-2024
Public Assessment Report Public Assessment Report Maltese 29-01-2024
Patient Information leaflet Patient Information leaflet Dutch 31-01-2024
Public Assessment Report Public Assessment Report Dutch 29-01-2024
Patient Information leaflet Patient Information leaflet Polish 31-01-2024
Public Assessment Report Public Assessment Report Polish 29-01-2024
Patient Information leaflet Patient Information leaflet Portuguese 31-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 31-01-2024
Public Assessment Report Public Assessment Report Portuguese 29-01-2024
Patient Information leaflet Patient Information leaflet Romanian 31-01-2024
Public Assessment Report Public Assessment Report Romanian 29-01-2024
Patient Information leaflet Patient Information leaflet Slovak 31-01-2024
Public Assessment Report Public Assessment Report Slovak 29-01-2024
Patient Information leaflet Patient Information leaflet Slovenian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 31-01-2024
Public Assessment Report Public Assessment Report Slovenian 29-01-2024
Patient Information leaflet Patient Information leaflet Finnish 31-01-2024
Public Assessment Report Public Assessment Report Finnish 29-01-2024
Patient Information leaflet Patient Information leaflet Swedish 31-01-2024
Public Assessment Report Public Assessment Report Swedish 29-01-2024
Patient Information leaflet Patient Information leaflet Norwegian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 31-01-2024
Public Assessment Report Public Assessment Report Norwegian 29-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 31-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 31-01-2024
Public Assessment Report Public Assessment Report Icelandic 29-01-2024
Patient Information leaflet Patient Information leaflet Croatian 31-01-2024
Public Assessment Report Public Assessment Report Croatian 29-01-2024

Search alerts related to this product

View documents history